Drugs / Enatumab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07190261 | Sep 2025 → Sep 2027 expected | autoimmune hemolytic anemia | Bing Han | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Enatumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07190261 ↗ |
| Action | Deplete | “inhibiting or eliminating abnormal plasma cells” NCT07190261 ↗ |
| Route | Subcutaneous | “recommended subcutaneous injection dose” NCT07190261 ↗ |